Functional MRI (fMRI) in CGRP Induced Migraine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00363532|
Recruitment Status : Completed
First Posted : August 15, 2006
Last Update Posted : January 28, 2009
In patients known with migraine without aura a migraine headache or migraine like headache will be induced by infusion of calcitonin gene related peptide (CGRP). The patients will then be stimulated with noxious heat via a thermode placed at the forehead. At the same time the Blood-oxygenation-level-dependent (BOLD) response will be measured via functional magnetic resonance imaging (fMRI), to estimate the central-nervous pain response. The regions of interest (ROI) will be thalamic region and medulla oblongata.
Then the patients will be given pain relif in form of injection of sumatriptan and the effect of this will also be registered via measuring the BOLD response at the RIO's previously defined. A 3-Tesla MRI scanner will be used in this trail.
This study will give us key knowledge of the trigeminal pain pathway and the central processing i.e sensitization during a migraine attach.
|Condition or disease||Intervention/treatment||Phase|
|Migraine Without Aura||Drug: infusion of calcitonin gene related peptide (CGRP)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Functional MRI (fMRI) in Patients With Migraine Without Aura Provoked by|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||July 2007|
|Actual Study Completion Date :||July 2007|
- Changes in BOLD response before and after CGRP infusion.
- Changes in BOLD response before and after injection of sumatriptan.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00363532
|Danish Headache Center, Neurological Dep. Glostrup hospital|
|Glostrup, Denmark, 2770|
|Study Chair:||Messoud Ashina, MD,PH.d||Danish Headache Center|